Hunter Associates Investment Management Lowers stake in Hologic (HOLX)

Hologic (HOLX) : Hunter Associates Investment Management reduced its stake in Hologic by 18.16% during the most recent quarter end. The investment management company now holds a total of 41,207 shares of Hologic which is valued at $1,593,887 after selling 9,143 shares in Hologic , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Hologic makes up approximately 0.67% of Hunter Associates Investment Management’s portfolio.

Other Hedge Funds, Including , Invictus Rg boosted its stake in HOLX in the latest quarter, The investment management firm added 3,231 additional shares and now holds a total of 3,791 shares of Hologic which is valued at $146,636. Hologic makes up approx 0.15% of Invictus Rg’s portfolio.Denver Investment Advisors reduced its stake in HOLX by selling 37,200 shares or 54.15% in the most recent quarter. The Hedge Fund company now holds 31,500 shares of HOLX which is valued at $1,223,775. Hologic makes up approx 0.05% of Denver Investment Advisors’s portfolio.Global X Management Co boosted its stake in HOLX in the latest quarter, The investment management firm added 268 additional shares and now holds a total of 1,549 shares of Hologic which is valued at $60,179.Eagleclaw Capital Managment boosted its stake in HOLX in the latest quarter, The investment management firm added 500 additional shares and now holds a total of 42,000 shares of Hologic which is valued at $1,631,700. Hologic makes up approx 1.04% of Eagleclaw Capital Managment’s portfolio.

Hologic opened for trading at $38.39 and hit $38.58 on the upside on Thursday, eventually ending the session at $38.46, with a gain of 0.10% or 0.04 points. The heightened volatility saw the trading volume jump to 16,99,124 shares. Company has a market cap of $10,670 M.

On the company’s financial health, Hologic reported $0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.48. The company had revenue of $717.40 million for the quarter, compared to analysts expectations of $703.38 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.

Many Wall Street Analysts have commented on Hologic. Company shares were Reiterated by RBC Capital Mkts on Aug 1, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 39 from a previous price target of $37 .

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.